Table 3.

Risk of serious infection among new users of targeted therapies for psoriatic arthritis from 2015 to 2021

	Unadjusted stabilised IPTW* Cox model†			Adjusted stabilised IPTW* Cox model†‡
	cHR	95% CI	P value	wHR	95% CI	P value
Treatments (reference: adalimumab)
Etanercept	0.72	0.54 to 0.96	0.0261	0.72	0.53 to 0.97	0.0305
Golimumab	0.79	0.39 to 1.60	0.5148	0.79	0.40 to 1.58	0.506
Certolizumab	0.86	0.48 to 1.54	0.6156	0.84	0.47 to 1.50	0.5488
Infliximab	2.01	0.67 to 6.02	0.2127	1.75	0.54 to 5.63	0.3486
Secukinumab	1.09	0.79 to 1.51	0.6015	1.07	0.77 to 1.50	0.6821
Ixekizumab	0.81	0.41 to 1.60	0.5383	0.77	0.38 to 1.57	0.4767
Ustekinumab	0.58	0.35 to 0.94	0.0258	0.57	0.35 to 0.93	0.0256
Tofacitinib	1.16	0.37 to 3.66	0.801	1.07	0.33 to 3.44	0.9089
Time-dependent covariates
csDMARDs	NA	NA	NA	0.9	0.71 to 1.15	0.4035
NSAIDs	NA	NA	NA	1.04	0.80 to 1.35	0.7668
Prednisone	NA	NA	NA	1.9	1.47 to 2.46	<0.0001

Values in bold correspond to significant results.

*Estimated with a multinomial logistic regression including age, sex, complementary universal health coverage, active skin psoriasis, diabetes, chronic heart failure, coronary heart disease, chronic respiratory disease, chronic liver disease, sequelae of stroke, obesity (proxy), tobacco use (proxy), alcohol intake, (proxy) consumption of csDMARDS, NSAIDs, or prednisone in the 2 years before inclusion and at inclusion, and weak and strong opioids analgesics use in the 2 years before inclusion.

†Using the Sandwich estimator, with adalimumab as the comparator.

‡Adjusted for time-dependent covariates (csDMARDs, NSAIDs, and prednisone) and calendar year.

cHR, crude HR; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; IPTW, inverse probability of treatment weighting; NA, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs; wHR, weighted HR.